phosphatidylcholines has been researched along with irinotecan in 9 studies
| Studies (phosphatidylcholines) | Trials (phosphatidylcholines) | Recent Studies (post-2010) (phosphatidylcholines) | Studies (irinotecan) | Trials (irinotecan) | Recent Studies (post-2010) (irinotecan) |
|---|---|---|---|---|---|
| 32,204 | 443 | 5,593 | 8,002 | 1,885 | 3,752 |
| Protein | Taxonomy | phosphatidylcholines (IC50) | irinotecan (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 2.7 | |
| Interstitial collagenase | Homo sapiens (human) | 6.06 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.556 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 3.171 | |
| Acetylcholinesterase | Homo sapiens (human) | 1.827 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 7.9 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 4.7667 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, I; Parmar, M; Peikov, V; Ugwu, S; Zhang, A | 1 |
| Cabral-Lilly, D; Cafiso, DS; Cho, C; Dicko, A; Ellena, JF; Frazier, AA; Hinderliter, A; Liboiron, BD; Mayer, LD; Tardi, PG; Weber, T; Xie, X | 1 |
| Gaud, R; Shende, P | 1 |
| Atyabi, F; Dinarvand, R; Esmaeili, F; Farkhondehfai, A | 1 |
| Anantha, M; Bally, M; Patankar, N; Ramsay, E; Waterhouse, D | 1 |
| Aljuffali, IA; Fang, JY; Huang, YJ; Sung, CT; Wen, CJ | 1 |
| Anantha, M; Bally, MB; Harasym, N; Manisali, I; Masin, D; Osooly, M; Ostlund, C; Santos, ND; Strutt, D; Sutherland, BW; Waterhouse, DN; Webb, MS; Wehbe, M | 1 |
| Du, Y; He, W; Li, X; Wang, J; Wang, T | 1 |
| Cheng, L; Du, Y; He, W; Li, X; Wang, J; Wang, T | 1 |
9 other study(ies) available for phosphatidylcholines and irinotecan
| Article | Year |
|---|---|
pH-dependent association of SN-38 with lipid bilayers of a novel liposomal formulation.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cardiolipins; Cholesterol; Chromatography, Gel; Diphenylhexatriene; Fluorescence Polarization; Fluorescent Dyes; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Irinotecan; Lipid Bilayers; Liposomes; Particle Size; Phosphatidylcholines; Temperature; Topoisomerase I Inhibitors | 2005 |
Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Calorimetry; Camptothecin; Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Cholesterol; Copper; Drug Carriers; Drug Compounding; Excipients; Floxuridine; Gluconates; Irinotecan; Liposomes; Magnetic Resonance Spectroscopy; Microscopy, Electron, Transmission; Phosphatidylcholines; Phosphatidylglycerols; Solubility; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet | 2008 |
Formulation and comparative characterization of chitosan, gelatin, and chitosan-gelatin-coated liposomes of CPT-11-HCl.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Chitosan; Cholesterol; Chromatography, High Pressure Liquid; Drug Carriers; Drug Compounding; Drug Stability; Electrochemistry; Freeze Fracturing; Gelatin; Irinotecan; Liposomes; Phosphatidylcholines | 2009 |
Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Drug Stability; Female; Injections, Intravenous; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C; Nanoparticles; Particle Size; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Solubility; Technology, Pharmaceutical; Tissue Distribution | 2009 |
The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C™.
Topics: Animals; Antineoplastic Agents; Calcimycin; Camptothecin; Cell Membrane Permeability; Chemistry, Pharmaceutical; Cholesterol; Chromatography, High Pressure Liquid; Copper; Female; Ionophores; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C; Phosphatidylcholines | 2011 |
Nanocomposite liposomes containing quantum dots and anticancer drugs for bioimaging and therapeutic delivery: a comparison of cationic, PEGylated and deformable liposomes.
Topics: Animals; Antineoplastic Agents; Calorimetry, Differential Scanning; Camptothecin; Cations; Cell Survival; Diagnostic Imaging; Drug Delivery Systems; Female; Irinotecan; Liposomes; Melanoma, Experimental; Mice; Mice, Nude; Nanocomposites; Particle Size; Phosphatidylcholines; Polyethylene Glycols; Quantum Dots; Spectrometry, Fluorescence; Static Electricity; Wound Healing | 2013 |
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cholesterol; Colon; Diarrhea; Disease Models, Animal; Drug Therapy, Combination; Female; Fluorouracil; Intestine, Small; Irinotecan; Liposomes; Nanoparticles; Phosphatidylcholines; Rats, Sprague-Dawley | 2014 |
Redox-sensitive irinotecan liposomes with active ultra-high loading and enhanced intracellular drug release.
Topics: Animals; Drug Liberation; Irinotecan; Liposomes; Oxidation-Reduction; Phosphatidylcholines | 2021 |
Dimeric Artesunate-Phosphatidylcholine-Based Liposomes for Irinotecan Delivery as a Combination Therapy Approach.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artesunate; Cell Line, Tumor; Drug Combinations; Drug Delivery Systems; Female; Irinotecan; Liposomes; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Phosphatidylcholines | 2021 |